Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.35 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564588 | 1.00 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5791770 | 0.79 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL4957051 | 0.75 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5789355 | 0.75 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| Glutamine SCHEMBL29009200 | 0.74 | KMT2A (0.73) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL21312920 | 0.74 | ALOX15 (0.46) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL6742412 | 0.73 | KMT2A (0.48) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL27888860 | 0.73 | GRIK1 (0.50) | ALOX15BLMPMP22KMT2AGRIK1 | |
| SCHEMBL10891103 | 0.73 | KMT2A (0.48) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL9791352 | 0.71 | ALOX15 (0.47) | ALOX15BLMPMP22KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| WO-2025081133-A2 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EXTRACELLULAR PROTEINS IN THE BRAIN | YALE UNIVERSITY (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2024227119-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-10-31 | — | — | WO | claimed |
| US-12083181-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024167879-A1 | BIFUNCTIONAL MOLECULES TO TARGET DEGRADATION OF INTERLEUKIN 17A (IL-17A) | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-08-15 | — | — | WO | claimed |
| WO-2024167900-A2 | BIFUNCTIONAL MOLECULES TO TARGET DEGRADATION OF TUMOR NECROSIS FACTOR | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-08-15 | — | — | WO | claimed |
| US-20240050578-A1 | BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS | UNIV YALE (US) | 2024-02-15 | — | — | US | claimed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | claimed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | claimed |
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | YALE UNIVERSITY | 2023-05-25 | — | — | US | claimed |
| US-20230097887-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2023-03-30 | — | — | US | claimed |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-03-16 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | disclosed |
| US-20260015402-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | YALE UNIVERSITY | 2026-01-15 | — | — | US | disclosed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4005600-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220111060-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | UNIV YALE (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220089579-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015402-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | CD2, CD74, CD2BP2 | ALOX15 4133/4885BLM 4567/4885PMP22 4111/4885 |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | ALOX15 1184/4885BLM 3567/4885PMP22 4066/4885 |
| US-20230097887-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, GMFG, SERPINA6 | ALOX15 1780/4885BLM 1022/4885PMP22 2789/4885 |
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | CD47, CD4, CD2 | ALOX15 4548/4885BLM 4725/4885PMP22 4438/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | ALOX15 1710/4885BLM 4213/4885PMP22 4189/4885 |
| US-20240050578-A1 | BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS | MIF, GMFG, FCGR1A | ALOX15 1522/4885BLM 1311/4885PMP22 3060/4885 |
| US-20220111060-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | FCGR1A, CD47, FCGR3B | ALOX15 4705/4885BLM 4135/4885PMP22 4373/4885 |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | ASGR1, LDLR, FCGR3B | ALOX15 1158/4885BLM 4498/4885PMP22 3873/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | ALOX15 1710/4885BLM 4213/4885PMP22 4189/4885 |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | ALOX15 4829/4885BLM 4440/4885PMP22 2849/4885 |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | ALOX15 1710/4885BLM 4213/4885PMP22 4189/4885 |
| US-20220089579-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | ALOX15 3713/4885BLM 4834/4885PMP22 1275/4885 |
| US-12083181-B2 | Bi-functional molecules to degrade circulating proteins | MIF, GMFG, FCGR1A | ALOX15 1522/4885BLM 1311/4885PMP22 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.